Cannabis Science Inc. (CBIS) Announces Progress in Bringing the First Cannabis Based Medicine to Market Company Moving Towards Contracts and Licensing Agreements for Research and Development of New Medicines
COLORADO SPRINGS, Colo.--(BUSINESS WIRE)--Cannabis Science Inc. (NASD OTCBB: CBIS), a pharmaceutical cannabis company in the US, is pleased to announce it is finalizing agreements with suppliers, manufactures, and research institutions that it expects will close within days and weeks to come. Once these agreements are closed they will be announced along with details on how CBIS will bring its first Cannabis based pharmaceutical products to market.
“We have worked hard to get to this point and look forward to sharing the details with our shareholders in a timely fashion, and we appreciate their continued support” stated Dr. Robert Melamede, President & CEO.
Cannabis Science is in negotiations with several companies in the US and internationally to contract or license its cannabis based formulations for development, certain rights to manufacturing processes, and sales in each prospective jurisdiction and or country.
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
Forward Looking Statements; This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.